Hyeong-Gon Moon

List of Publications by Year
in descending order

175	4,237	101496	155592
papers	citations	36 h-index	55 g-index

182	182	182	6972
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Clinical application of shear wave elastography (SWE) in the diagnosis of benign and malignant breast diseases. Breast Cancer Research and Treatment, 2011, 129, 89-97.	1.1	300
2	Visceral Obesity May Affect Oncologic Outcome in Patients with Colorectal Cancer. Annals of Surgical Oncology, 2008, 15, 1918-1922.	0.7	174
3	Galectin-1 expression in cancer-associated stromal cells correlates tumor invasiveness and tumor progression in breast cancer. International Journal of Cancer, 2007, 120, 2331-2338.	2.3	150
4	Tumor Suppressor miRNA-204-5p Regulates Growth, Metastasis, and Immune Microenvironment Remodeling in Breast Cancer. Cancer Research, 2019, 79, 1520-1534.	0.4	126
5	Underweight and Breast Cancer Recurrence and Death: A Report From the Korean Breast Cancer Society. Journal of Clinical Oncology, 2009, 27, 5899-5905.	0.8	91
6	Breast density change as a predictive surrogate for response to adjuvant endocrine therapy in hormone receptor positive breast cancer. Breast Cancer Research, 2012, 14, R102.	2.2	86
7	The prevalence and spectrum of BRCA1 and BRCA2 mutations in Korean population: recent update of the Korean Hereditary Breast Cancer (KOHBRA) study. Breast Cancer Research and Treatment, 2015, 151, 157-168.	1.1	82
8	Breast MR Imaging Screening in Women with a History of Breast Conservation Therapy. Radiology, 2014, 272, 366-373.	3.6	81
9	Integrative analysis of mutational and transcriptional profiles reveals driver mutations of metastatic breast cancers. Cell Discovery, 2016, 2, 16025.	3.1	77
10	Ki-67 Expression Gives Additional Prognostic Information on St. Gallen 2007 and Adjuvant! Online Risk Categories in Early Breast Cancer. Annals of Surgical Oncology, 2009, 16, 1112-1121.	0.7	76
11	Common Genetic Variants Associated with Breast Cancer in Korean Women and Differential Susceptibility According to Intrinsic Subtype. Cancer Epidemiology Biomarkers and Prevention, 2011, 20, 793-798.	1.1	68
12	Factors associated with upstaging from ductal carcinoma in situ following core needle biopsy to invasive cancer in subsequent surgical excision. Breast, 2012, 21, 641-645.	0.9	63
13	Prognostic and functional importance of the engraftment-associated genes in the patient-derived xenograft models of triple-negative breast cancers. Breast Cancer Research and Treatment, 2015, 154, 13-22.	1.1	62
14	Transglutaminase 2 facilitates the distant hematogenous metastasis of breast cancer by modulating interleukin-6 in cancer cells. Breast Cancer Research, 2011, 13, R96.	2.2	60
15	Unilateral Breast Cancer: Screening of Contralateral Breast by Using Preoperative MR Imaging Reduces Incidence of Metachronous Cancer. Radiology, 2013, 267, 57-66.	3.6	56
16	NFIB is a potential target for estrogen receptorâ€negative breast cancers. Molecular Oncology, 2011, 5, 538-544.	2.1	54
17	Phase II randomized trial of neoadjuvant metformin plus letrozole versus placebo plus letrozole for estrogen receptor positive postmenopausal breast cancer (METEOR). BMC Cancer, 2014, 14, 170.	1.1	54
18	COX2 overexpression is a prognostic marker for Stage III breast cancer. Breast Cancer Research and Treatment, 2012, 132, 51-59.	1.1	52

#	Article	IF	Citations
19	Age and HER2 expression status affect MRI accuracy in predicting residual tumor extent after neo-adjuvant systemic treatment. Annals of Oncology, 2009, 20, 636-641.	0.6	51
20	Proteomic Approach Reveals FKBP4 and S100A9 as Potential Prediction Markers of Therapeutic Response to Neoadjuvant Chemotherapy in Patients with Breast Cancer. Journal of Proteome Research, 2012, 11, 1078-1088.	1.8	51
21	Limited Value and Utility of Breast MRI in Patients Undergoing Breast-Conserving Cancer Surgery. Annals of Surgical Oncology, 2012, 19, 2572-2579.	0.7	51
22	Breast-Conserving Surgery After Tumor Downstaging by Neoadjuvant Chemotherapy is Oncologically Safe for Stage III Breast Cancer Patients. Annals of Surgical Oncology, 2013, 20, 2582-2589.	0.7	51
23	Prognostic influence of BCL2 expression in breast cancer. International Journal of Cancer, 2012, 131, E1109-19.	2.3	50
24	Role Of Ultrasonography in Predicting Malignancy in Patients with Thyroid Nodules. World Journal of Surgery, 2007, 31, 1410-1416.	0.8	47
25	Survival Outcomes of Breast Cancer Patients Who Receive Neoadjuvant Chemotherapy: Association with Dynamic Contrast-enhanced MR Imaging with Computer-aided Evaluation. Radiology, 2013, 268, 662-672.	3.6	47
26	Distinctive role of SIRT1 expression on tumor invasion and metastasis in breast cancer by molecular subtype. Human Pathology, 2015, 46, 1027-1035.	1.1	47
27	Transition into inflammatory cancer-associated adipocytes in breast cancer microenvironment requires microRNA regulatory mechanism. PLoS ONE, 2017, 12, e0174126.	1.1	47
28	The value of preoperative staging chest computed tomography to detect asymptomatic lung and liver metastasis in patients with primary breast carcinoma. Breast Cancer Research and Treatment, 2011, 126, 637-641.	1.1	46
29	The association between physical activity and health-related quality of life among breast cancer survivors. Health and Quality of Life Outcomes, 2017, 15, 132.	1.0	45
30	SIRT1 induces tumor invasion by targeting epithelial mesenchymal transition-related pathway and is a prognostic marker in triple negative breast cancer. Tumor Biology, 2016, 37, 4743-4753.	0.8	43
31	Nomogram for predicting positive resection margins after breast-conserving surgery. Breast Cancer Research and Treatment, 2012, 134, 1115-1123.	1.1	42
32	Early Stage Triple-Negative Breast Cancer: Imaging and Clinical-Pathologic Factors Associated with Recurrence. Radiology, 2016, 278, 356-364.	3.6	42
33	Thyrotropin Level and Thyroid Volume for Prediction of Hypothyroidism Following Hemithyroidectomy in an Asian Patient Cohort. World Journal of Surgery, 2008, 32, 2503-8.	0.8	39
34	Shear-Wave Elastographic Features of Breast Cancers. Investigative Radiology, 2014, 49, 147-155.	3.5	39
35	Recurrent fusion transcripts detected by wholeâ€transcriptome sequencing of 120 primary breast cancer samples. Genes Chromosomes and Cancer, 2015, 54, 681-691.	1.5	38
36	Predictive Significance of p53, Ki-67, and Bcl-2 Expression for Pathologic Complete Response after Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer. Journal of Breast Cancer, 2015, 18, 16.	0.8	38

#	Article	IF	Citations
37	Overexpression of HIF1Î± and CAXI predicts poor outcome in early-stage triple negative breast cancer. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2016, 469, 183-190.	1.4	38
38	Prediction of axillary lymph node metastasis in primary breast cancer patients using a decision tree-based model. BMC Medical Informatics and Decision Making, 2012, 12, 54.	1.5	36
39	Oncogenic role of SIRT1 associated with tumor invasion, lymph node metastasis, and poor disease-free survival in triple negative breast cancer. Clinical and Experimental Metastasis, 2016, 33, 179-185.	1.7	36
40	Management of benign papilloma without atypia diagnosed at ultrasound-guided core needle biopsy: Scoring system for predicting malignancy. European Journal of Surgical Oncology, 2018, 44, 53-58.	0.5	36
41	Breast Cancer Molecular Phenotype and the Use of HER2-Targeted Agents Influence the Accuracy of Breast MRI After Neoadjuvant Chemotherapy. Annals of Surgery, 2013, 257, 133-137.	2.1	35
42	Residual Mammographic Microcalcifications and Enhancing Lesions on MRI After Neoadjuvant Systemic Chemotherapy for Locally Advanced Breast Cancer: Correlation with Histopathologic Residual Tumor Size. Annals of Surgical Oncology, 2016, 23, 1135-1142.	0.7	35
43	Identifying the potential long-term survivors among breast cancer patients with distant metastasis. Annals of Oncology, 2016, 27, 828-833.	0.6	34
44	Comparison of the diagnostic performance of digital breast tomosynthesis and magnetic resonance imaging added to digital mammography in women with known breast cancers. European Radiology, 2016, 26, 1556-1564.	2.3	32
45	Long-term effect of aromatase inhibitors on bone microarchitecture and macroarchitecture in non-osteoporotic postmenopausal women with breast cancer. Osteoporosis International, 2017, 28, 1413-1422.	1.3	32
46	MR imaging features associated with distant metastasis-free survival of patients with invasive breast cancer: a caseâ€“control study. Breast Cancer Research and Treatment, 2017, 162, 559-569.	1.1	32
47	Adenoid Cystic Carcinoma of the Breast: A Case Series of Six Patients and Literature Review. Cancer Research and Treatment, 2014, 46, 93-97.	1.3	32
48	Young age is associated with ipsilateral breast tumor recurrence after breast conserving surgery and radiation therapy in patients with HER2-positive/ER-negative subtype. Breast Cancer Research and Treatment, 2011, 130, 499-505.	1.1	31
49	Endoscopic Thyroidectomy Using a Gasless Axillary Approach. Journal of Laparoendoscopic and Advanced Surgical Techniques - Part A, 2007, 17, 21-25.	0.5	30
50	Delay of Treatment Initiation Does Not Adversely Affect Survival Outcome in Breast Cancer. Cancer Research and Treatment, 2016, 48, 962-969.	1.3	30
51	Decreased annexin A3 expression correlates with tumor progression in papillary thyroid cancer. Proteomics - Clinical Applications, 2010, 4, 528-537.	0.8	29
52	Mammographic features of calcifications in DCIS: correlation with oestrogen receptor and human epidermal growth factor receptor 2 status. European Radiology, 2013, 23, 2072-2078.	2.3	28
53	Detection of Germline Mutations in Breast Cancer Patients with Clinical Features of Hereditary Cancer Syndrome Using a Multi-Gene Panel Test. Cancer Research and Treatment, 2020, 52, 697-713.	1.3	28
54	Discordant ER, PR, and HER2 status between primary and metastatic breast cancer as prognostic factor.. Journal of Clinical Oncology, 2013, 31, 1039-1039.	0.8	28

#	Article	IF	Citations
55	Reliability of Sentinel Lymph Node Biopsy after Neoadjuvant Chemotherapy in Breast Cancer Patients. Journal of Breast Cancer, 2013, 16, 378.	0.8	27
56	Is the high proportion of young age at breast cancer onset a unique feature of Asian breast cancer?. Breast Cancer Research and Treatment, 2019, 173, 189-199.	1.1	27
57	Comparable Survival Between pN0 Breast Cancer Patients Undergoing Sentinel Node Biopsy and Extensive Axillary Dissection: A Report From the Korean Breast Cancer Society. Journal of Clinical Oncology, 2010, 28, 1692-1699.	0.8	25
58	Shear-Wave Elastography for the Detection of Residual Breast Cancer After Neoadjuvant Chemotherapy. Annals of Surgical Oncology, 2015, 22, 376-384.	0.7	25
59	Dietary pattern and health-related quality of life among breast cancer survivors. BMC Women's Health, 2018, 18, 65.	0.8	25
60	Prognostic effect of preoperative serum estradiol level in postmenopausal breast cancer. BMC Cancer, 2013, 13, 503.	1.1	24
61	Risk Factors Associated with Distant Metastasis and Survival Outcomes in Breast Cancer Patients with Locoregional Recurrence. Journal of Breast Cancer, 2015, 18, 160.	0.8	24
62	Enhanced anti-tumor activity and cytotoxic effect on cancer stem cell population of metformin-butyrate compared with metformin HCl in breast cancer. Oncotarget, 2016, 7, 38500-38512.	0.8	24
63	Can We Skip Intraoperative Evaluation of Sentinel Lymph Nodes? Nomogram Predicting Involvement of Three or More Axillary Lymph Nodes before Breast Cancer Surgery. Cancer Research and Treatment, 2017, 49, 1088-1096.	1.3	24
64	Expression of SIRT1 and apoptosis-related proteins is predictive for lymph node metastasis and disease-free survival in luminal A breast cancer. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2015, 467, 563-570.	1.4	23
65	Reproductive factors as risk modifiers of breast cancer in BRCA mutation carriers and high-risk non-carriers. Oncotarget, 2017, 8, 102110-102118.	0.8	23
66	Preoperative serum tissue polypeptideâ€specific antigen is a valuable prognostic marker in breast cancer. International Journal of Cancer, 2013, 132, 875-881.	2.3	22
67	Tissue transglutaminase-interleukin-6 axis facilitates peritoneal tumor spreading and metastasis of human ovarian cancer cells. Laboratory Animal Research, 2015, 31, 188.	1.1	22
68	Malignant peripheral nerve sheath tumor arising from the colon in a newborn: report of a case and review of the literatures. Journal of Pediatric Surgery, 2006, 41, e19-e22.	0.8	21
69	Evaluation of tumor extent in breast cancer patients using real-time MR navigated ultrasound: Preliminary study. European Journal of Radiology, 2012, 81, 3208-3215.	1.2	21
70	The Value of Ki67 in Very Young Women with Hormone Receptor-Positive Breast Cancer: Retrospective Analysis of 9,321 Korean Women. Annals of Surgical Oncology, 2015, 22, 3481-3488.	0.7	20
71	New insight on the biological role of p53 protein as a tumor suppressor: re-evaluation of its clinical significance in triple-negative breast cancer. Tumor Biology, 2016, 37, 11017-11024.	0.8	20
72	Different prognosis of young breast cancer patients in their 20s and 30s depending on subtype: a nationwide study from the Korean Breast Cancer Society. Breast Cancer Research and Treatment, 2017, 166, 833-842.	1.1	20

#	Article	IF	Citations
73	Adherence to Guidelines for Cancer Survivors and Health-Related Quality of Life among Korean Breast Cancer Survivors. Nutrients, 2015, 7, 10307-10319.	1.7	19
74	In Vivo Tumor Growth Rate Measured by US in Preoperative Period and Long Term Disease Outcome in Breast Cancer Patients. PLoS ONE, 2015, 10, e0144144.	1.1	19
75	Prognostic Influence of BCL2 on Molecular Subtypes of Breast Cancer. Journal of Breast Cancer, 2017, 20, 54.	0.8	19
76	Breast Sparganosis Presenting as a Breast Mass with Vague Migrating Pain. Journal of the American College of Surgeons, 2008, 207, 292.	0.2	18
77	Up-regulation of RhoGDI2 in Human Breast Cancer and Its Prognostic Implications. Cancer Research and Treatment, 2010, 42, 151.	1.3	18
78	Perspective Insight into Future Potential Fusion Gene Transcript Biomarker Candidates in Breast Cancer. International Journal of Molecular Sciences, 2018, 19, 502.	1.8	17
79	JAK2 regulates paclitaxel resistance in triple negative breast cancers. Journal of Molecular Medicine, 2021, 99, 1783-1795.	1.7	17
80	Development and Validation of a Novel Plasma Protein Signature for Breast Cancer Diagnosis by Using Multiple Reaction Monitoring-based Mass Spectrometry. Anticancer Research, 2015, 35, 6271-9.	0.5	17
81	Grade of Ductal Carcinoma In Situ Accompanying Infiltrating Ductal Carcinoma As an Independent Prognostic Factor. Clinical Breast Cancer, 2013, 13, 385-391.	1.1	16
82	Transfer-RNA-mediated enhancement of ribosomal proteins S6 kinases signaling for cell proliferation. RNA Biology, 2018, 15, 635-648.	1.5	16
83	Effect of multiple invasive foci on breast cancer outcomes according to the molecular subtypes: a report from the Korean Breast Cancer Society. Annals of Oncology, 2013, 24, 2298-2304.	0.6	15
84	Low Rates of Additional Cancer Detection by Magnetic Resonance Imaging in Newly Diagnosed Breast Cancer Patients Who Undergo Preoperative Mammography and Ultrasonography. Journal of Breast Cancer, 2014, 17, 167.	0.8	15
85	Factors associated with late recurrence after completion of 5-year adjuvant tamoxifen in estrogen receptor positive breast cancer. BMC Cancer, 2016, 16, 430.	1.1	15
86	Development of a Nomogram to Predict the Recurrence Score of 21-Gene Prediction Assay in Hormone Receptorâ€“Positive Early Breast Cancer. Clinical Breast Cancer, 2020, 20, 98-107.e1.	1.1	15
87	Oncologic outcomes after immediate breast reconstruction following mastectomy: comparison of implant and flap using propensity score matching. BMC Cancer, 2020, 20, 78.	1.1	15
88	S100A8/A9 mediate the reprograming of normal mammary epithelial cells induced by dynamic cellâ€“cell interactions with adjacent breast cancer cells. Scientific Reports, 2021, 11, 1337.	1.6	15
89	The Clinical Significance and Molecular Features of the Spatial Tumor Shapes in Breast Cancers. PLoS ONE, 2015, 10, e0143811.	1.1	15
90	Cowden Syndrome Presenting as Breast Cancer: Imaging and Clinical Features. Korean Journal of Radiology, 2014, 15, 586.	1.5	14

#	Article	IF	Citations
91	Immune recurrence score using 7 immunoregulatory protein expressions can predict recurrence in stage Iâ€“III breast cancer patients. British Journal of Cancer, 2019, 121, 230-236.	2.9	14
92	Estrogen receptor status confers a distinct pattern of response to neoadjuvant chemotherapy: implications for optimal durations of therapy. Breast Cancer Research and Treatment, 2012, 134, 1133-1140.	1.1	13
93	Validation of a Scoring System for Predicting Malignancy in Patients Diagnosed with Atypical Ductal Hyperplasia Using an Ultrasound-Guided Core Needle Biopsy. Journal of Breast Cancer, 2012, 15, 407.	0.8	13
94	Clinical Usefulness of AJCC Response Criteria for Neoadjuvant Chemotherapy in Breast Cancer. Annals of Surgical Oncology, 2013, 20, 2242-2249.	0.7	12
95	Survival Improvement in Korean Breast Cancer Patients Due to Increases in Early-Stage Cancers and Hormone Receptor Positive/HER2 Negative Subtypes: A Nationwide Registry-Based Study. Journal of Breast Cancer, 2015, 18, 8.	0.8	12
96	Prognostic Role of Androgen Receptor Expression in Surgically Resected Early Breast Cancer Patients. Journal of Breast Cancer, 2020, 23, 182.	0.8	12
97	Landscape of Actionable Genetic Alterations Profiled from 1,071 Tumor Samples in Korean Cancer Patients. Cancer Research and Treatment, 2019, 51, 211-222.	1.3	12
98	Comparative characterization of 3D chromatin organization in triple-negative breast cancers. Experimental and Molecular Medicine, 2022, 54, 585-600.	3.2	12
99	Targeting epidermal growth factor receptor in paclitaxel-resistant human breast and lung cancer cells with upregulated glucose-6-phosphate dehydrogenase. British Journal of Cancer, 2022, 127, 661-674.	2.9	12
100	The use of FNA samples for wholeâ€exome sequencing and detection of somatic mutations in breast cancer surgical specimens. Cancer Cytopathology, 2015, 123, 669-677.	1.4	11
101	Prognostic impact of AJCC response criteria for neoadjuvant chemotherapy in stage II/III breast cancer patients: breast cancer subtype analyses. BMC Cancer, 2016, 16, 515.	1.1	11
102	Effects of tamoxifen and aromatase inhibitors on the risk of acute coronary syndrome in elderly breast cancer patients: An analysis of nationwide data. Breast, 2020, 54, 25-30.	0.9	11
103	Ki-67 Expression is a Significant Prognostic Factor Only When Progesterone Receptor Expression is Low in Estrogen Receptor-Positive and HER2-Negative Early Breast Cancer. Journal of Oncology, 2019, 2019, 1-8.	0.6	11
104	A Validation Study of a Multiple Reaction Monitoring-Based Proteomic Assay to Diagnose Breast Cancer. Journal of Breast Cancer, 2019, 22, 579.	0.8	11
105	Phosphorylation of p90RSK is associated with increased response to neoadjuvant chemotherapy in ER-positive breast cancer. BMC Cancer, 2012, 12, 585.	1.1	10
106	Loss of ataxia-telangiectasia-mutated protein expression correlates with poor prognosis but benefits from anthracycline-containing adjuvant chemotherapy in breast cancer. Breast Cancer Research and Treatment, 2016, 158, 233-241.	1.1	10
107	Prognostic Impact of Pregnancy in Korean Patients with Breast Cancer. Oncologist, 2019, 24, e1268-e1276.	1.9	10
108	Association between Number of Retrieved Sentinel Lymph Nodes and Breast Cancer-related Lymphedema. Journal of Breast Cancer, 2021, 24, 63.	0.8	10

#	Article	IF	Citations
109	Calsequestrin 2 overexpression in breast cancer increases tumorigenesis and metastasis by modulating the tumor microenvironment. Molecular Oncology, 2022, 16, 466-484.	2.1	10
110	Diffusion-weighted Breast MRI in Prediction of Upstaging in Women with Biopsy-proven Ductal Carcinoma in Situ. Radiology, 2022, 305, 307-316.	3.6	10
111	A histomorphologic predictive model for axillary lymph node metastasis in preoperative breast cancer core needle biopsy according to intrinsic subtypes. Human Pathology, 2015, 46, 246-254.	1.1	9
112	RORÎ±2 requires LSD1 to enhance tumor progression in breast cancer. Scientific Reports, 2017, 7, 11994.	1.6	9
113	Prognostic role of body mass index is different according to menopausal status and tumor subtype in breast cancer patients. Breast Cancer Research and Treatment, 2019, 176, 453-460.	1.1	9
114	Nomogram for Predicting Breast Conservation after Neoadjuvant Chemotherapy. Cancer Research and Treatment, 2015, 47, 197-207.	1.3	8
115	A proposal for a new classification of T4 breast cancer as stage IIIC: a report from the Korean Breast Cancer Society. Breast Cancer Research and Treatment, 2015, 153, 153-160.	1.1	8
116	Prognostic effects of abnormal DNA damage response protein expression in breast cancer. Breast Cancer Research and Treatment, 2019, 175, 117-127.	1.1	8
117	Association of Insulin, Metformin, and Statin with Mortality in Breast Cancer Patients. Cancer Research and Treatment, 2021, 53, 65-76.	1.3	8
118	Development of a FFQ for breast cancer survivors in Korea. British Journal of Nutrition, 2016, 116, 1781-1786.	1.2	7
119	Time interval of neoadjuvant chemotherapy to surgery in breast cancer: how long is acceptable?. Gland Surgery, 2017, 6, 1-3.	0.5	7
120	Effect of standard low-dose anthracycline chemotherapy on late congestive heart failure in breast cancer survivors aged between 50 and 59Âat diagnosis: A nationwide study. Breast, 2020, 53, 125-129.	0.9	7
121	Endocrine Treatment-Related Symptoms and Patient Outcomes in Breast Cancer: A Meta-Analysis. Journal of Breast Cancer, 2018, 21, 37.	0.8	6
122	Intensity of metastasis screening and survival outcomes in patients with breast cancer. Scientific Reports, 2021, 11, 2851.	1.6	6
123	Dietary Intake Status among Korean Female Breast Cancer Survivors. Korean Journal of Community Nutrition, 2014, 19, 163.	0.1	6
124	The value of intraoperative imprint cytology in the assessment of lymph node status in gastric cancer surgery. Gastric Cancer, 2005, 8, 245-248.	2.7	5
125	Factors Affecting the Ipsilateral Breast Tumor Recurrence after Breast Conserving Therapy in Patients with T1 and T2 Tumors. Journal of Breast Cancer, 2009, 12, 324.	0.8	5
126	Patients with Concordant Triple-Negative Phenotype between Primary Breast Cancers and Corresponding Metastases Have Poor Prognosis. Journal of Breast Cancer, 2016, 19, 268.	0.8	5

#	Article	IF	Citations
127	Personalized neoadjuvant strategy in luminal A breast cancer to increase breast conserving surgery (BCS) rate [PLATO study].. Journal of Clinical Oncology, 2020, 38, TPS603-TPS603.	0.8	5
128	Protein Phosphatase 1H, Cyclin-Dependent Kinase Inhibitor p27, and Cyclin-Dependent Kinase 2 in Paclitaxel Resistance for Triple Negative Breast Cancers. Journal of Breast Cancer, 2020, 23, 162.	0.8	5
129	Ki-67 level in hormone reptor positive breast cancer patients: A retrospective review of 9,061 Korean women.. Journal of Clinical Oncology, 2013, 31, 551-551.	0.8	5
130	17p12 deletion in breast cancer predicts resistance to neoadjuvant chemotherapy. Experimental and Therapeutic Medicine, 2011, 2, 799-804.	0.8	4
131	Efficacy of Exemestane in Korean Patients with Metastatic Breast Cancer after Failure of Nonsteroidal Aromatase Inhibitors. Journal of Breast Cancer, 2013, 16, 66.	0.8	4
132	Reduced proliferation in breast cancer cells contacting the neighboring adipocytes in human breast cancer tissues. Breast Cancer Research, 2015, 17, 90.	2.2	4
133	The Association between the Adherence to Dietary Guidelines for Breast Cancer Survivors and Health-related Quality of Life among Korean Breast Cancer Survivors. Korean Journal of Community Nutrition, 2015, 20, 129.	0.1	4
134	The treatment outcomes and the use of adjuvant therapies in breast cancer patients with severe co-morbidities. PLoS ONE, 2017, 12, e0173721.	1.1	4
135	An objective nodal staging system for breast cancer patients undergoing neoadjuvant systemic treatment. BMC Cancer, 2017, 17, 389.	1.1	3
136	Dynamic and subtype-specific interactions between tumour burden and prognosis in breast cancer. Scientific Reports, 2020, 10, 15445.	1.6	3
137	Patient-Derived Xenograft Models in Breast Cancer Research. Advances in Experimental Medicine and Biology, 2021, 1187, 283-301.	0.8	3
138	Nutrient intakes from supplement and factors associated with supplement use among breast cancer survivors: A crossâ€sectional study. European Journal of Cancer Care, 2021, 30, e13447.	0.7	3
139	Actual Conversion Rate from Total Mastectomy to Breast Conservation after Neoadjuvant Chemotherapy for Stages Iiâ€“III Breast Cancer Patients. Journal of Breast Disease, 2017, 5, 51-56.	0.2	3
140	Abstract PD15-08: Window of opportunity trial of neoadjuvant olaparib and durvalumab for triple negative or low ER-positive breast cancer. Cancer Research, 2022, 82, PD15-08-PD15-08.	0.4	3
141	Polo-Like Kinase 1 Regulates Chromosomal Instability and Paclitaxel Resistance in Breast Cancer Cells. Journal of Breast Cancer, 2022, 25, 178.	0.8	3
142	Clinicopathological Characteristics and Factors Affecting Recurrence of Ductal CarcinomaIn Situin Korean Women. Journal of Breast Cancer, 2010, 13, 392.	0.8	2
143	The Effect of Reproductive Factors on Breast Cancer Presentation in Women Who Are BRCA Mutation Carrier. Journal of Breast Cancer, 2017, 20, 279.	0.8	2
144	Effect of prolonged cold ischemic time on immunohistochemical testing of estrogen receptor, progesterone receptor, and HER2 expression in breast cancer.. Journal of Clinical Oncology, 2014, 32, e11505-e11505.	0.8	2

#	Article	IF	Citations
145	The Impact of Primary Tumor Resection on the Survival of Patients with Stage IV Breast Cancer. Journal of Breast Cancer, 2010, 13, 90.	0.8	1
146	Limitations of Conventional Contrast-enhanced MRI in Selecting Sentinel Node Biopsy Candidates among DCIS Patients. Journal of Breast Cancer, 2010, 13, 154.	0.8	1
147	Impact of Chemotherapy-Induced Ovarian Dysfunction on Response to Neoadjuvant Chemotherapy in Breast Cancer. Annals of Surgical Oncology, 2015, 22, 391-397.	0.7	1
148	FoxM1 as a potential therapeutic target for triple-negative breast cancer.. Journal of Clinical Oncology, 2013, 31, e22063-e22063.	0.8	1
149	Clinical Implication of Galectin-1 Expression in Human Breast Cancer. Journal of Breast Cancer, 2006, 9, 36.	0.8	1
150	Efficacy of Letrozole as First-Line Treatment of Postmenopausal Women with Hormone Receptorâ€“Positive Metastatic Breast Cancer in Korea. Cancer Research and Treatment, 2017, 49, 454-463.	1.3	1
151	Efficacy of Breast Ultrasonography for Detection of Local, Regional, and Contralateral Recurrence of Breast Cancer. Journal of Breast Cancer, 2010, 13, 403.	0.8	1
152	Breast Cancer: Serum TPS as a Biomarker. Biomarkers in Disease, 2015, , 417-427.	0.0	1
153	The Roles of Modern Breast Imaging Techniques for Evaluation of Lobular Carcinoma <i>In Situ</i> of the Breast. Journal of Breast Disease, 2015, 3, 71-76.	0.2	1
154	Mastocheck: Notable plasma protein biomarker for diagnosis of breast cancer in the real clinical practice by using multiple reaction monitoring-based mass spectrometry.. Journal of Clinical Oncology, 2019, 37, 3044-3044.	0.8	1
155	Reply to M.-H. Tan et al. Journal of Clinical Oncology, 2010, 28, e178-e179.	0.8	0
156	Breast Cancer: Serum TPS as a Biomarker. , 2014, , 1-9.		0
157	Usefulness of staging chest-CT in patients with operable breast cancer. PLoS ONE, 2021, 16, e0246563.	1.1	0
158	Abstract PS10-13: Impact of trastuzumab on Ipsilateral breast tumor recurrence after breast conserving surgery. , 2021, , .		0
159	The Emotional Status, Attitudes in Decision-Making Process, and Their Impact on Surgical Choices in Korean Breast Cancer Patients. Journal of Oncology, 2021, 2021, 1-6.	0.6	0
160	Thyroidectomy in Patients with Hashimoto's Thyroiditis Presenting as a Distinct Thyroid Nodule. The Korean Journal of Endocrine Surgery, 2007, 7, 155.	0.1	0
161	The role and significance of FoxM1 in invasive breast cancer.. Journal of Clinical Oncology, 2012, 30, 1056-1056.	0.8	0
162	Identification and validation of plasma protein biomarker panels for breast cancer diagnosis by using multiple reaction monitoring-based mass spectrometry.. Journal of Clinical Oncology, 2012, 30, 10621-10621.	0.8	0

#	Article	IF	Citations
163	Breast-conserving surgery after neoadjuvant chemotherapy for stage III breast cancer patients.. Journal of Clinical Oncology, 2012, 30, e11532-e11532.	0.8	0
164	Nomogram for predicting breast-conservation surgery after neoadjuvant chemotherapy.. Journal of Clinical Oncology, 2013, 31, 1128-1128.	0.8	0
165	Factors associated with adherence to adjuvant endocrine therapy in patients with hormone receptor positive breast cancer.. Journal of Clinical Oncology, 2014, 32, e11502-e11502.	0.8	0
166	Dietary patterns and healthâ€related quality of life among Korean breast cancer survivors. FASEB Journal, 2015, 29, 736.3.	0.2	0
167	A proposal for a new classification of T4 breast cancer as stage IIIC.. Journal of Clinical Oncology, 2015, 33, e11585-e11585.	0.8	0
168	Correlation between tumor-free axillary lymph node morphology and clinicopathologic features in invasive breast cancer.. Journal of Clinical Oncology, 2015, 33, e12059-e12059.	0.8	0
169	The Effect of Cold Ischemic Time on Immunohistochemical Evaluation of Invasive Ductal Carcinoma. Journal of Breast Disease, 2015, 3, 60-64.	0.2	0
170	Clinical significance of axillary lymph node count in axillary dissection following neoadjuvant chemotherapy for breast cancer.. Journal of Clinical Oncology, 2016, 34, e12508-e12508.	0.8	0
171	Correlation of loss of ataxia-telangiectasia-mutated protein expression with poor prognosis and benefit from anthracycline containing adjuvant chemotherapy in breast cancer.. Journal of Clinical Oncology, 2016, 34, e23268-e23268.	0.8	0
172	A survey investigating the current situation of the international visiting scholar program at the department of surgery in Korea. Annals of Surgical Treatment and Research, 2020, 99, 189.	0.4	0
173	Abstract P2-11-07: Mammographic density is associated with increased risk of contralateral breast cancers but not of ipsilateral breast tumor recurrences. Cancer Research, 2022, 82, P2-11-07-P2-11-07.	0.4	0
174	Abstract P3-18-12: Achieving negative margin after repeated attempts for lumpectomy does not nullify the risk of ipsilateral breast tumor recurrences. Cancer Research, 2022, 82, P3-18-12-P3-18-12.	0.4	0
175	Abstract 6241: Macc1 regulates breast cancer progression and metastasis via remodeling tumor immune microenvironment. Cancer Research, 2022, 82, 6241-6241.	0.4	0